Wuhan Union Hospital

Running trials

• Not yet recruiting

  A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)

  NCT07915219· Phase 3· Boehringer Ingelheim· Source

• Not yet recruiting

  A Study of HS-10382 Versus Investigator-selected TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

  NCT07885293· Phase 3· Jiangsu Hansoh Pharmaceutical Co., Ltd.· Source

• Not yet recruiting

  AIM2-NLRP3 Inflammasome Dual Inhibitor on hsCRP

  NCT07933757· Union Hospital, Tongji Medical College, Huazhong University of Science and Technology· Source

• Not yet recruiting

  Phase III Study of HS-20089 With Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer

  NCT07821606· Phase 3· Hansoh BioMedical R&D Company· Source

• Not yet recruiting

  A Prospective, Biomarker-Stratified Phase 2 Study: β-Hydroxybutyrate as a Predictive Biomarker for Short-Course Radiotherapy Followed by Chemotherapy Plus PD-1 Inhibitor Versus Chemotherapy Alone in Locally Advanced Rectal Cancer

  NCT07847229· Phase 2· Tao Zhang· Source

• Not yet recruiting

  TQB2922 Injection Given Under the Skin With Chemotherapy as Initial Treatment for Colorectal Cancer That Has Spread

  NCT07844187· Phase 1/2· Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.· Source

• Recruiting

  A Study Comparing BL-B01D1 in Combination With PD-1/VEGF Bispecific Antibody Versus Chemotherapy in Combination With PD-1/VEGF Bispecific Antibody in First-line Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer(PANKU-Lung05)

  NCT07739199· Phase 2/3· Sichuan Baili Pharmaceutical Co., Ltd.· Source

• Not yet recruiting

  Quad Shot Radiotherapy Combined With Tislelizumab and Platinum-Based Chemotherapy Before Surgery for Stage II-III Non-Small Cell Lung Cancer

  NCT07845916· Phase 2· Union Hospital, Tongji Medical College, Huazhong University of Science and Technology· Source

• Recruiting

  Finerenone in Patients Undergoing Transcatheter Aortic Valve Implantation With Heart Failure

  NCT07575672· Phase 3· Second Affiliated Hospital, Zhejiang University, School of Medicine· Source

• Recruiting

  Iparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus

  NCT07776080· Phase 2· Union Hospital, Tongji Medical College, Huazhong University of Science and Technology· Source

• Not yet recruiting

  A Prospective, Multicenter,Single-arm Study of DuoCor 2 Ventricular Assist System for the Treatment of Advanced Biventricular Heart Failure

  NCT07757451· Shenzhen Core Medical Technology CO.,LTD.· Source

• Not yet recruiting

  Albumin-Bound Paclitaxel (Ⅱ) in Patients With Advanced Breast Cancer

  NCT07899047· Union Hospital, Tongji Medical College, Huazhong University of Science and Technology· Source

• Not yet recruiting

  Union-LC-MPE Cohort:A Multicenter Cohort Study on Diagnosis and Prognosis of Malignant Pleural Effusion in Lung Cance

  NCT07882758· Union Hospital, Tongji Medical College, Huazhong University of Science and Technology· Source

• Not yet recruiting

  Ciprofol, Propofol and Sevoflurane for Postoperative Delirium in Elderly Brain Tumor Patients

  NCT07799623· Union Hospital, Tongji Medical College, Huazhong University of Science and Technology· Source

• Recruiting

  QLESP Block for Pain Control in Robotic Partial Nephrectomy

  NCT07704970· Huazhong University of Science and Technology· Source

• Recruiting

  A Study of ATG-022 Compared With Investigator's Choice of Treatment in Claudin 18.2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

  NCT07795346· Phase 3· Antengene Biologics Limited· Source

• Recruiting

  Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)

  NCT07687459· Phase 3· InSilico Medicine Hong Kong Limited· Source

• Recruiting

  A Clinical Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Patients With HER2-Abnormally Expressed Unresectable Locally Advanced or Metastatic Colorectal Cancer.

  NCT07653685· Phase 1/2· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source

• Not yet recruiting

  A Phase II Study of VB19055 in Uncontrolled or Resistant Hypertension

  NCT07833098· Phase 2· Zhejiang Yangli Pharmaceutical Technology Co., Ltd.· Source

• Recruiting

  Efficacy and Safety of Telitacicept in the Treatment of Refractory Rheumatoid Arthritis

  NCT07796516· Phase 2· Peking University People's Hospital· Source

• Recruiting

  A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation

  NCT07678593· Phase 1/2· Genfleet Therapeutics (Shanghai) Inc.· Source

• Not yet recruiting

  Rituximab, Pirtobrutinib, Lisaftoclax and Liposomal Mitoxantrone for for Richter Syndrome Transformed From CLL

  NCT07831395· Phase 2· Institute of Hematology & Blood Diseases Hospital, China· Source

• Not yet recruiting

  Exploring the Efficacy of Ferrous Sulfate/Ferrous Succinate Combined With Serplulimab and SOX Regimen in Neoadjuvant Therapy for Gastric Cancer: A Prospective Cohort Study

  NCT07872696· Phase 2· Union Hospital, Tongji Medical College, Huazhong University of Science and Technology· Source

• Not yet recruiting

  AI-Assisted Chest CT Interpretation Across the Lung Cancer Care Continuum

  NCT07829640· Union Hospital, Tongji Medical College, Huazhong University of Science and Technology· Source

• Not yet recruiting

  A Phase 2 Study of ABSK043 Combined With Osimertinib

  NCT07710612· Phase 2· Abbisko Therapeutics Co, Ltd· Source

• Not yet recruiting

  Multi-Omics Prediction of Radiation Lung Injury in Immunotherapy-Treated Lung Cancer Patients

  NCT07742800· HAN GUANG· Source

• Recruiting

  SMP-656 for HER2-Positive Advanced Breast Cancer

  NCT07726342· Phase 2· Chengdu SciMount Pharmatech Co., Ltd.· Source

• Recruiting

  A Study of Econoglutide Injection in Obese Participants With Knee Osteoarthritis (KOA)

  NCT07734311· Phase 3· Hangzhou Sciwind Biosciences Co., Ltd.· Source

• Not yet recruiting

  Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of TJ0113 Capsules in Patients With Early-Onset Parkinson's Disease

  NCT07741045· Phase 3· Hangzhou PhecdaMed Co., Ltd.· Source

• Recruiting

  IBI363 Combined With Bevacizumab for Advanced Colorectal Cancer

  NCT07722494· Phase 3· Innovent Biologics (Suzhou) Co. Ltd.· Source

• Recruiting

  Efficacy and Safety of Retlirafusp Alfa Plus Bevacizumab and Chemotherapy With or Without Short-Course Radiotherapy in Patients With CRCLM

  NCT07728019· Phase 2· Union Hospital, Tongji Medical College, Huazhong University of Science and Technology· Source

• Active, not recruiting

  Validation of a Deep Learning Tool for Opportunistic Osteoporosis Screening Using Routine Non-Contrast CT Scans

  NCT07739628· Union Hospital, Tongji Medical College, Huazhong University of Science and Technology· Source

• Recruiting

  A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors

  NCT07518043· Phase 1· Shanghai Henlius Biotech· Source

• Recruiting

  Non-stenting Treatment Strategy for Acute Myocardial Infarction With Non-severe Stenosis(EROSION IV)

  NCT07567625· Harbin Medical University· Source

• Not yet recruiting

  A Phase II Study of H021 Enteric-coated Tablets for Moderately to Severely Active Crohn's Disease

  NCT07677514· Phase 2· Jiangsu Carephar Pharmaceutical Co., Ltd.· Source

• Recruiting

  Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer

  NCT07476287· Phase 2· Pfizer· Source

• Not yet recruiting

  Clinical Application Value of Deep Learning-Based "Opportunistic Screening" for Malignant Tumors on Routine Non-Contrast Chest-Abdomen-Pelvis CT

  NCT07639567· Lian Yang· Source

• Recruiting

  Metabolic and Functional Study of γδ T Cells in Critically Ill Patients

  NCT07680816· Union Hospital, Tongji Medical College, Huazhong University of Science and Technology· Source

• Enrolling by invitation

  Predictive Efficacy of Fecal Calprotectin Assay by Magnetic Particle Chemiluminescence for Mucosal Healing in Moderate-to-Severe Ulcerative Colitis Patients Undergoing Initial Biologic Therapy（PRECAL）

  NCT07721441· Tang-Du Hospital· Source

• Not yet recruiting

  A Clinical Study for the Safety and Efficacy of BL0020 Injection in Combination With Toripalimab Injection in Patients With Recurrent Extensive-Stage Small Cell Lung Cancer

  NCT07550842· Phase 1· Shanghai Best-Link Bioscience, LLC· Source

• Recruiting

  A Study of IN026 in Participants With Refractory Gout

  NCT07587684· Phase 1· Union Hospital, Tongji Medical College, Huazhong University of Science and Technology· Source

• Active, not recruiting

  The Clinical Application Value of CAIX-Targeted PET Hypoxia Imaging in Malignant Tumors

  NCT07890038· Union Hospital, Tongji Medical College, Huazhong University of Science and Technology· Source

• Recruiting

  SG301-SC Injection Safety Study in Subjects With Primary ITP Patients

  NCT07710248· Phase 2· Hangzhou Sumgen Biotech Co., Ltd.· Source

• Recruiting

  Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer

  NCT07552402· Harbin Medical University· Source

• Recruiting

  A Clinical Study of [68Ga]Ga-ELI421 Injection PET Imaging in Patients With Prostate Cancer

  NCT07689656· Phase 1/2· Union Hospital, Tongji Medical College, Huazhong University of Science and Technology· Source

• Not yet recruiting

  Metformin Combined With Secukinumab for Moderate-to-Severe Plaque Psoriasis in Overweight or Obese Chinese Patients

  NCT07485764· Phase 4· Union Hospital, Tongji Medical College, Huazhong University of Science and Technology· Source

• Not yet recruiting

  Treatment of Recurrent/Metastatic Head and Neck Cancer

  NCT07601204· Phase 1/2· Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.· Source

• Not yet recruiting

  Effects of Inulin on Cardiometabolic Risk Factors in Individuals Using Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA ) Medications for Weight Loss

  NCT07611552· Huazhong University of Science and Technology· Source

• Not yet recruiting

  Blood Exosomal Multi-omics and Lung Radiomics for Predicting Efficacy and Prognosis of Severe Eosinophilic ACOS With Biologics

  NCT07602881· Union Hospital, Tongji Medical College, Huazhong University of Science and Technology· Source

• Not yet recruiting

  Phase III Clinical Trial of Changji'an Capsules in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea (Liver-Qi Invading Spleen Syndrome)

  NCT07610434· Phase 3· Beijing Hospital of Traditional Chinese Medicine· Source

Showing 50 of 441.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer54 recruiting
• Colorectal cancer26 recruiting
• Childhood cancers16 recruiting
• Gastric and oesophageal cancer16 recruiting
• Immune thrombocytopenia (ITP)13 recruiting
• Lupus (SLE)13 recruiting
• Acute lymphoblastic leukaemia12 recruiting
• Pancreatic cancer12 recruiting
• Head and neck cancer11 recruiting
• Liver and biliary tract cancer11 recruiting
• Bronchiectasis10 recruiting
• Multiple myeloma10 recruiting
• Prostate cancer8 recruiting
• Chronic lymphocytic leukaemia7 recruiting
• Metastatic breast cancer7 recruiting
• Rheumatoid arthritis7 recruiting
• Sarcoma7 recruiting
• Acute myeloid leukaemia6 recruiting
• Diffuse large B-cell lymphoma6 recruiting
• Kidney cancer6 recruiting
• Ovarian cancer6 recruiting
• Heart failure5 recruiting
• Melanoma5 recruiting
• Bladder cancer4 recruiting
• Cervical cancer4 recruiting
• Follicular lymphoma4 recruiting
• High blood pressure4 recruiting
• Liver cirrhosis4 recruiting
• Psoriasis4 recruiting
• Coronary artery disease3 recruiting
• Dilated cardiomyopathy3 recruiting
• Endometrial cancer3 recruiting
• Hepatitis B3 recruiting
• Obesity3 recruiting
• Osteoarthritis3 recruiting
• Systemic sclerosis (scleroderma)3 recruiting
• Triple-negative breast cancer3 recruiting
• Ulcerative colitis3 recruiting
• Asthma2 recruiting
• Crohn's disease2 recruiting
• Fatty liver disease (MASLD/MASH)2 recruiting
• Glioblastoma2 recruiting
• Mantle cell lymphoma2 recruiting
• Myelodysplastic syndromes2 recruiting
• Myeloproliferative neoplasms2 recruiting
• Thyroid cancer2 recruiting
• Alzheimer disease1 recruiting
• Aplastic anaemia1 recruiting
• Brain metastases1 recruiting
• Chronic kidney disease1 recruiting
• Chronic myeloid leukaemia1 recruiting
• Chronic rhinosinusitis with nasal polyps1 recruiting
• Congenital heart disease1 recruiting
• COPD1 recruiting
• Cytomegalovirus infection1 recruiting
• Deep vein thrombosis and pulmonary embolism1 recruiting
• Gout1 recruiting
• Haemophagocytic lymphohistiocytosis1 recruiting
• Haemophilia1 recruiting
• Idiopathic pulmonary fibrosis1 recruiting
• IgA nephropathy1 recruiting
• Irritable bowel syndrome1 recruiting
• Macular degeneration1 recruiting
• Mild cognitive impairment1 recruiting
• Mitochondrial disease1 recruiting
• Myasthenia gravis1 recruiting
• Myocarditis1 recruiting
• Neuroendocrine tumours1 recruiting
• Osteoporosis1 recruiting
• Parkinson disease1 recruiting
• Primary biliary cholangitis1 recruiting
• Psoriatic arthritis1 recruiting
• Pulmonary arterial hypertension1 recruiting
• Spinal cord injury1 recruiting
• Stroke1 recruiting
• Trigeminal neuralgia1 recruiting

Closed trials

• Withdrawn

  A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Autoimmune Diseases

  NCT07583030· Early phase 1· Union Hospital, Tongji Medical College, Huazhong University of Science and Technology· Source

• Completed

  A Research Study of House Dust Mite (HDM) SLIT-tablet for the Treatment of HDM Allergy in Chinese Participants Aged 12-65

  NCT07060885· Phase 3· ALK-Abelló A/S· Source

• Completed

  The Clinical Application Value of SPECT Imaging Targeting LRRC15 in Malignant Tumors

  NCT07651020· Union Hospital, Tongji Medical College, Huazhong University of Science and Technology· Source

• Recruiting

  A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of Tacabrutideg (BGB-16673) in Adults With Chronic Spontaneous Urticaria and in Healthy Participants

  NCT07005713· Phase 1· BeOne Medicines· Source

• Withdrawn

  A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases

  NCT06869278· Phase 1· Union Hospital, Tongji Medical College, Huazhong University of Science and Technology· Source

• Completed

  A First-in-Human Study of ¹⁷⁷Lu-HX02 in Sarcoma Patients

  NCT07847268· Union Hospital, Tongji Medical College, Huazhong University of Science and Technology· Source

• Completed

  A Study of LCAR-AIO in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus

  NCT06653556· Early phase 1· Union Hospital, Tongji Medical College, Huazhong University of Science and Technology· Source

• Completed

  End-expiratory Transpulmonary Pressure-guided vs Electrical Impedance Tomography-guided PEEP Titration Methods in Patients With Intra-abdominal Hypertension Combined With Acute Respiratory Distress Syndrome: a Randomized Crossover Controlled Study

  NCT06697717· XiaoJing Zou,MD· Source

• Completed

  A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections

  NCT06439342· Phase 3· Takeda· Source

• Completed

  Pharmacokinetic Interactions Between Hemay005 Tablets and Midazolam Maleate Tablets

  NCT06610890· Phase 1· Ganzhou Hemay Pharmaceutical Co., Ltd· Source

• Completed

  A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors

  NCT06549816· Phase 1· Seagen, a wholly owned subsidiary of Pfizer· Source

• Completed

  Long-term Safety and Efficacy of TQH2722 Injection in the Treatment of Chronic Sinusitis With or Without Nasal Polyps

  NCT06439381· Phase 2· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

• Completed

  DuoCor Ventricular Assist System Early Feasibility Study

  NCT06878508· Shenzhen Core Medical Technology CO.,LTD.· Source

• Completed

  To Evaluate the Pharmacokinetics of Hemay005 Tablets in Patients With Renal Impairment

  NCT06380153· Phase 1· Ganzhou Hemay Pharmaceutical Co., Ltd· Source

• Completed

  [68Ga]Ga-GZP PET for Early Response Prediction in Colorectal Cancer During Neoadjuvant Therapy

  NCT06982053· Union Hospital, Tongji Medical College, Huazhong University of Science and Technology· Source

• Completed

  A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis

  NCT06280716· Phase 3· Eli Lilly and Company· Source

• Completed

  A Clinical Study of TK216 in Patients With Relapsed or Refractory Ewing's Sarcoma

  NCT05046314· Phase 2· Shanghai Pharmaceuticals Holding Co., Ltd· Source

• Completed

  A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose Weight

  NCT06214741· Phase 3· Boehringer Ingelheim· Source

• Completed

  RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

  NCT06173037· Phase 2· RemeGen Co., Ltd.· Source

• Completed

  A Clinical Study of JS005 in Patients With Ankylosing Spondylitis

  NCT06250062· Phase 2· Shanghai Junshi Bioscience Co., Ltd.· Source

• Completed

  A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight

  NCT06066528· Phase 3· Boehringer Ingelheim· Source

• Completed

  A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment

  NCT06088043· Phase 3· Takeda· Source

• Completed

  A Study of Gimistotug (BGB-A445) in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer

  NCT06029127· Phase 2· BeiGene· Source

• Completed

  Tobramycin Inhalation Solution for Pseudomonas Aeruginosa Eradication in Bronchiectasis

  NCT06093191· Phase 4· Jin-Fu Xu· Source

• Completed

  Different Doses of Colchicine on hsCRP

  NCT06078904· Phase 4· Union Hospital, Tongji Medical College, Huazhong University of Science and Technology· Source

• Completed

  A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06049017· Phase 2· Janssen Research & Development, LLC· Source

• Completed

  Donor Circadian Rhythm and Its Correlation With Prognosis After Heart Transplantation

  NCT07301788· Union Hospital, Tongji Medical College, Huazhong University of Science and Technology· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

  NCT05894239· Phase 3· Hoffmann-La Roche· Source

• Completed

  Evaluating Different Doses of Orelabrutinib in MCL

  NCT05978739· Phase 2· InnoCare Pharma Inc.· Source

• Completed

  Phase II Clinical Trial of OPS-2071 in the Treatment of Irritable Bowel Syndrome of Diarrhea Type

  NCT05923892· Phase 2· Otsuka Beijing Research Institute· Source

• Completed

  Effect of APRV vs. LTV on Right Heart Function in ARDS Patients: a Single-center Randomized Controlled Study

  NCT05922631· XiaoJing Zou,MD· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

  NCT05646862· Phase 3· Hoffmann-La Roche· Source

• Completed

  A Study of DS-7011a in Patients With Systemic Lupus Erythematosus

  NCT05638802· Phase 1/2· Daiichi Sankyo· Source

• Completed

  A Psychosocial Dyadic Programme for Patients With Heart Failure and Their Family Caregivers

  NCT05864469· The University of Hong Kong· Source

• Completed

  A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  NCT05704738· Phase 3· Amgen· Source

• Completed

  Lunsayil 1: A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa

  NCT05819398· Phase 2/3· Boehringer Ingelheim· Source

• Completed

  Study of Telitacicept in Generalized Myasthenia Gravis

  NCT05737160· Phase 3· RemeGen Co., Ltd.· Source

• Completed

  A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia A

  NCT05707351· Phase 3· Takeda· Source

• Completed

  A Study of Letermovir (MK-8228) to Evaluate Efficacy and Safety for Prevention of Cytomegalovirus Infection in Chinese Hematopoietic Stem Cell Transplant Recipients (MK-8228-045)

  NCT05763823· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney Disease

  NCT05593575· Phase 2· Shanghai Pharmaceuticals Holding Co., Ltd· Source

• Completed

  A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

  NCT05687032· Phase 4· Pfizer· Source

• Completed

  A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)

  NCT05724199· Phase 3· Amgen· Source

• Completed

  A Trial of Y101D in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Advanced Pancreatic Cancer

  NCT06266143· Phase 1/2· Wuhan YZY Biopharma Co., Ltd.· Source

• Terminated

  A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma

  NCT05590377· Phase 1/2· Teva Branded Pharmaceutical Products R&D LLC· Source

• Completed

  A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms

  NCT05559580· Phase 2· Boehringer Ingelheim· Source

• Terminated

  Study of BN301, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies

  NCT05611853· Phase 1/2· BioNova Pharmaceuticals (Shanghai) LTD.· Source

• Completed

  ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

  NCT05507203· Phase 3· Abivax S.A.· Source

• Completed

  A Phase I Study to Evaluate the Safety and Tolerability of JL15003 Injection in Patients With Recurrent Glioblastoma

  NCT07497373· Phase 1· Jecho Biopharmaceuticals Co., Ltd.· Source

• Completed

  A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)

  NCT05508867· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT05321069· Phase 3· Boehringer Ingelheim· Source

Showing 50 of 117.

Conditions

Diseases this institution publishes on or runs trials for.

• Lung cancer139 works · 105 trials
• Liver and biliary tract cancer95 works · 17 trials
• Colorectal cancer73 works · 37 trials
• Gastric and oesophageal cancer48 works · 28 trials
• Pancreatic cancer29 works · 18 trials
• Ovarian cancer29 works · 15 trials
• Hearing loss28 works · 1 trial
• Glioblastoma27 works · 4 trials
• Kidney cancer23 works · 12 trials
• Osteoporosis22 works · 4 trials
• Cervical cancer22 works · 8 trials
• Diffuse large B-cell lymphoma15 works · 20 trials
• Aortic aneurysm14 works · 0 trials
• Acute lymphoblastic leukaemia14 works · 16 trials
• Endometrial cancer14 works · 6 trials
• Myocarditis13 works · 1 trial
• Chronic myeloid leukaemia10 works · 1 trial
• Thyroid cancer10 works · 4 trials
• Irritable bowel syndrome6 works · 2 trials
• Immune thrombocytopenia (ITP)5 works · 14 trials
• Aplastic anaemia3 works · 1 trial